A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C

Abstract

� 2016 The Author(s). Background: High-throughput technologies have the potential to identify non-invasive biomarkers of liver pathology and improve our understanding of basic mechanisms of liver injury and repair. A metabolite profiling approach was employed to determine associations between alterations in serum metabolites and liver histology in patients with chronic hepatitis C virus (HCV) infection. Methods: Sera from 45 non-diabetic patients with chronic HCV were quantitatively analyzed using 1 H-NMR spectroscopy. A metabolite profile of advanced fibrosis (METAVIR F3-4) was established using orthogonal partial least squares discriminant analysis modeling and validated using seven-fold cross-validation and permutation testing. Bioprofiles of moderate to severe steatosis (≥33 %) and necroinflammation (METAVIR A2-3) were also derived. The classification accuracy of these profiles was determined using areas under the receiver operator curves (AUROCSs) measuring against liver biopsy as the gold standard. Results: In total 63 spectral features were profiled, of which a highly significant subset of 21 metabolites were associated with advanced fibrosis (variable importance score > 1 in multivariate modeling; R 2 = 0.673 and Q 2 = 0.285). For the identification of F3-4 fibrosis, the metabolite bioprofile had an AUROC of 0.86 (95 % CI 0.74-0.97). The AUROCs for the bioprofiles for moderate to severe steatosis were 0.87 (95 % CI 0.76-0.97) and for grade A2-3 inflammation were 0.73 (0.57-0.89). Conclusion: This proof-of-principle study demonstrates the utility of a metabolomics profiling approach to non-invasively identify biomarkers of liver fibrosis, steatosis and inflammation in patients with chronic HCV. Future cohorts are necessary to validate these findings.